BioSpace News Archive

The Children’s National Research & Innovation Campus will be the first in the nation dedicated to pediatric research

Respicardia has announced 5-year results from the remedē System Post Approval Study, assessing the safety and efficacy of transvenous phrenic nerve stimulation for the treatment of moderate to severe central sleep apnea (CSA).

Sarissa Capital Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 17,500,000 units, at a price of $10.00 per unit. The Company’s sponsor, Sarissa Capital Acquisition Sponsor LLC (the “Sponsor”), was capitalized by investment funds managed by Sarissa Capital Management LP , which was

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that new data for its early detection ELSA-seq test will be presented at the upcoming European Society for Medical Oncology (ESMO) Asia Virtual Congress, on Friday, November 20.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2020 before the U.S. market opens on November 20, 2020.